Patents Examined by Marianne P. Allen
  • Patent number: 11396539
    Abstract: The present invention relates to new anti-angiopoietin 2 (ANGPT2) neutralizing antibodies for therapeutic and diagnostic methods and composition using them.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: July 26, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ryan Michael Fryer, Chao Zheng, Michael Dziegelewski, Pankaj Gupta
  • Patent number: 11390672
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 19, 2022
    Assignee: Janssen Biotech, Inc.
    Inventor: John Simard
  • Patent number: 11390677
    Abstract: The present invention provides antibodies that bind to CD47 with high affinity and specificity, and their use in treatment of a cancer.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 19, 2022
    Assignee: TRICAN BIOTECHNOLOGY CO., LTD.
    Inventors: Huang-Tsu Chen, Jiun-Shyang Leou, Chung-Yuan Hsu, Cheng-Ke Li, Yun-Ting Wang, Li-Tsen Lin, Shiou-Ting Chen, Chen-Wei Chiang
  • Patent number: 11370834
    Abstract: The application belongs to the technical field of biomedicines and provides an improved anti-Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) monoclonal antibody and an application thereof. By a computer-aided simulation design, a novel phage antibody library is designed, and an improved anti-VEGFR-2 monoclonal antibody is obtained after multiple rounds of screening. Both affinity and biological activity of the antibody are higher than those of an original antibody. The antibody is capable of effectively inhibiting combination of VEGFR-2 and a ligand Vascular Endothelial Growth Factor (VEGF) thereof in vitro, and may be used in treating a tumor and a disease caused by angiogenesis such as macular degeneration.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 28, 2022
    Assignee: BEIJING DONGFANG BIOTECH CO., LTD.
    Inventors: Yi Bai, Xiangguo Gu
  • Patent number: 11358994
    Abstract: The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Syndrome (SBS) are also described.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: June 14, 2022
    Assignee: Saint Louis University
    Inventors: Marvin J. Meyers, David C. Wood, Stacy D. Arnett, Matthew P. Yates, Peter G. Ruminski
  • Patent number: 11352420
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 7, 2022
    Assignee: PARACRINE THERAPEUTICS AB
    Inventors: Ulf Eriksson, Hong Li, Andrew Scott, Laura Allan
  • Patent number: 11351231
    Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: June 7, 2022
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Jonathan LeBowitz, John Maga
  • Patent number: 11325969
    Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind FGL2. The disclosure is also directed to uses of the antibodies and binding fragments thereof for treating cancer.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: May 10, 2022
    Assignee: Veritas Therapeutics Inc.
    Inventors: Gary Levy, Ramzi Khattar, Andrzej Chruscinski, Barbara Vanderhyden, Curtis McCloskey
  • Patent number: 11324805
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryo Ohori, Kanta Horie
  • Patent number: 11324834
    Abstract: Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: May 10, 2022
    Assignee: IGF Oncology, LLC
    Inventors: Hugh McTavish, Arkadiusz Z. Dudek
  • Patent number: 11325960
    Abstract: The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 10, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Masashi Shimizu, Toshitaka Sato, Yoshihisa Arita
  • Patent number: 11319364
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which a is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: May 3, 2022
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • Patent number: 11312765
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: April 26, 2022
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • Patent number: 11312764
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: April 26, 2022
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • Patent number: 11299528
    Abstract: Methods of treating an autoimmune disease such as rheumatoid arthritis, methods of increasing apoptosis of pro-inflammatory immune cells or synoviocytes, methods of increasing the quantity of the anti-inflammatory regulatory T cells, and methods of slowing the progression of inflammation in a subject include systemically administering to the subject a pharmaceutical composition including an effective amount of a TRAIL-conjugate. Preferably, the TRAIL-conjugate is effective for at least 3 days, more preferably at least 7 days, without being part of a nanocomplex that modulates the circulation half-life or release kinetics of the TRAIL-conjugate. Combination therapies including administering a second active agent, most preferably a TNF-? inhibitor, as well as pharmaceutical composition dosage units including a TRAIL-conjugate and a TNF-? inhibitor in an effective amount for a single once weekly dose for treatment of rheumatoid arthritis are also provided.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: April 12, 2022
    Assignee: D&D PHARMATECH INC.
    Inventors: Kang Choon Lee, Ha Na Eom
  • Patent number: 11298413
    Abstract: The present disclosure relates to CCL22 as a novel T cell target in cancer immunosuppression.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 12, 2022
    Assignee: IO BIOTECH APS
    Inventor: Mads Hald Andersen
  • Patent number: 11299538
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: April 12, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Eric Borges, Robert Rauchenberger, Gabriela Wochnik-Veltrup
  • Patent number: 11266708
    Abstract: The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc?RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 8, 2022
    Assignee: SUPPREMOL GMBH
    Inventors: Peter Sondermann, Thomas Pohl
  • Patent number: 11267855
    Abstract: Engineered FGF1 and FGF2 polypeptides, polynucleotides encoding these polypeptides and DNA constructs, vectors and compositions including these engineered polypeptides are provided herein. The engineered FGF1 and FGF2 polypeptides are more stable than their wild-type counterparts and may be more effective at treating a variety of conditions that FGF1 and FGF2 are useful for treating such as wound healing.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: March 8, 2022
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Suresh Kumar Thallapuranam, Shilpi Agarwal, Ravi Kumar Gundampati, Srinivas Jayanthi, Tengjiao Wang, Jake Jones, Olivia Kolenc, Ngoc Lam, Isabelle Niyonshuti, Kartik Balachandran, Kyle Quinn, Jingyi Chen
  • Patent number: 11254723
    Abstract: Provided are a mutated nucleic acid molecule of a recombinant human-basic fibroblast growth factor (rh-bFGF), a pharmaceutical composition of the rh-bFGF, and a use thereof.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: February 22, 2022
    Assignee: Zhuhai Essex Bio-Pharmaceutical Co., Ltd.
    Inventors: Haizhou Fang, Peimin Dai, Bo Yang, Xinzhi Wang, Zhenheng Wang, Malcolm Ngiam, Qi Xue, Yingluo Xiong